Rapt Therapeutics, Inc. Stock Price, News & Analysis

RAPT Therapeutics has announced the appointment of Jennifer Nicholson as Senior Vice President of Regulatory Affairs and Quality Assurance, and Adnan Rahman as Vice President of Commercial. These appointments come at a crucial time as the company progresses its RPT193 program into late-phase trials for atopic dermatitis and asthma, and continues developing FLX475 for various cancers. Both executives bring extensive experience from notable biopharmaceutical companies, which will enhance RAPT's regulatory and commercial strategies.

RAPT Therapeutics announced participation in key investor conferences throughout September 2022. The events include Citi’s 17th Annual Biopharma Conference on September 7, Wells Fargo Healthcare Conference on September 8 featuring a fireside chat with President and CEO Brian Wong, and H.C. Wainwright 24th Annual Global Investment Conference on September 12, available on-demand. RAPT is focused on developing small molecule therapies for inflammatory diseases and oncology, including drug candidates RPT193 and FLX475. For live webcasts, visit their website.

RAPT Therapeutics, a clinical-stage biopharmaceutical company, reported financial results for Q2 and the first half of 2022, marking a net loss of $19.2 million for Q2, compared to $16.1 million in Q2 2021. R&D expenses rose to $14.4 million from $13.2 million, driven by costs associated with RPT193. General and administrative expenses also increased to $5.4 million, up from $3.8 million. The company maintains a robust cash position of $207.3 million, bolstered by a $50 million financing. Future plans include expanding RPT193 trials and advancing FLX475.

RAPT Therapeutics, Inc. (Nasdaq: RAPT) has announced a $50 million private investment in public equity (PIPE) financing with the Redmile Group. The transaction involves pre-funded warrants for up to 4 million shares at $12.4999 each, based on the closing price on May 24, 2022. Gross proceeds are approximately $50 million before expenses, with closure expected by May 27, 2022. The company will file a registration statement to register the resale of these shares. This move supports RAPT's focus on developing oral small molecule therapies for inflammatory diseases and oncology.

RAPT Therapeutics has initiated a 16-week Phase 2b clinical trial for RPT193, an oral therapy aimed at treating moderate-to-severe atopic dermatitis (AD). This randomized, double-blind, placebo-controlled study will assess multiple doses of RPT193 and aims to confirm its efficacy and safety. Previous Phase 1b results indicated significant improvements in key efficacy measures and no serious adverse events. The trial's co-primary endpoints include the percent change in the Eczema Area and Severity Index (EASI) and the incidence of treatment-emergent adverse events.

RAPT Therapeutics, Inc. (Nasdaq: RAPT) reported Q1 2022 financial results, revealing a net loss of $20.5 million, up from $16.5 million in Q1 2021. Research and development expenses increased to $16.7 million due to clinical trial costs for RPT193 and FLX475. General and administrative expenses rose to $4.7 million. The company is advancing its clinical trials, including initiating a Phase 2b trial for RPT193 in atopic dermatitis and a Phase 2a trial for asthma. RAPT maintains a solid cash position of $173.0 million.

RAPT Therapeutics, Inc. (Nasdaq: RAPT) recently announced key leadership appointments, including Gwen Carscadden as Chief Human Resources Officer, Jim Farmer as Vice President of Clinical Operations, and Shari Geffon as Vice President of Program and Alliance Management. These hires are seen as pivotal in advancing RPT193 and FLX475 through clinical development. The company aims to address significant unmet needs in inflammatory diseases and oncology, leveraging the extensive experience of these new executives in their respective fields.

RAPT Therapeutics has reported promising biomarker data from its Phase 1b trial of RPT193 for moderate-to-severe atopic dermatitis, presented at the American Academy of Dermatology Annual Meeting. Key findings indicate a statistically significant improvement in the meta-analysis derived atopic dermatitis (MADAD) score (p<0.001) and positive changes in immune pathways linked to the disease. RAPT aims to initiate a Phase 2b clinical trial in atopic dermatitis, with plans to expand RPT193's development into asthma.

RAPT Therapeutics, Inc. reported its financial results for Q4 2021 and the full year, highlighting a net loss of $17.9 million for Q4 and $69.2 million for the year, an increase from $12.7 million and $52.9 million in 2020, respectively. R&D expenses rose to $14.3 million in Q4 and $57.0 million for the year due to clinical trial costs for RPT193 and FLX475. General and administrative expenses also increased to $4.5 million in Q4 and $16.0 million for the year. The company maintained a robust cash position of $189.7 million as of year-end.